Key result
Rivaroxaban had a stronger inhibitory effect on FX activity and venous stasis thrombosis when administered at the beginning of the light phase compared to the dark phase in rats.
Rivaroxaban effects vary by circadian phase in rats; leaves open whether dosing timing affects human outcomes.
The anticoagulant effect of rivaroxaban, a direct inhibitor of activated factor X (FX), might be influenced by its dosing time because the activity of the coagulofibrinolytic system exhibits daily rhythmicity. In rats, FX activity follows a 24-h rhythm with a peak in the middle of the light phase and a trough at the beginning of the dark phase. Consistent with these findings, a single dose of rivaroxaban had a stronger inhibitory effect on FX activity after dosing at the beginning of the light phase than after dosing at the beginning of the dark phase. A similar chronopharmacological effect was seen in a quantitative model of venous stasis thrombosis. In comparison, the dosing time had minimal influence on the pharmacokinetics of rivaroxaban. These data indicate that the anticoagulant effect of rivaroxaban is influenced by the dosing time. Further studies should confirm this finding in a clinical setting.
No takes yet. Share an insight, caveat, or question.
Fujiwara et al. (2017) studied Coagulation activity. Rivaroxaban vs. Dosing at the beginning of the dark phase was evaluated on FX activity and venous stasis thrombosis. Rivaroxaban had a stronger inhibitory effect on FX activity and venous stasis thrombosis when administered at the beginning of the light phase compared to the dark phase in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: